

Dear Editor,

We submit the revised version of our invited editorial titled "Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: is there a benefit?", Manuscript No 66467, for consideration for publication in the World Journal of Gastroenterology. We thank the Reviewer for his/her comments, which improved our paper. We modified the text accordingly. All changes are shown in red in the revised manuscript.

The paper has not been published before and is not under consideration for publication elsewhere. We have no conflict of interest to declare. This is an invited editorial and the invited manuscript ID is 00036318.

Response to Reviewer's comments

Reviewer's code: 00008736

Treatment options for NAFLD and NASH are still limited. The authors describe some recent findings of inhibitors of Acetyl-CoA carboxylase in animal models and clinical studies. Overall, this is a brief and up-to-date editorial on the topic, which is of high relevance to the field. A table summarizing the preclinical and clinical findings should be added.

We thank this Reviewer for stating "Overall, this is a brief and up-to-date editorial on the topic, which is of high relevance to the field." We added a table summarizing the preclinical and clinical findings.

Best regards,

Konstantinos Tziomalos, MD, MSc, PhD

Associate Professor of Internal Medicine

Medical School, Aristotle University of Thessaloniki, Greece